Sotac Pharmaceuticals Ltd

Sotac Pharmaceuticals Ltd has witnessed a significant shift in its valuation parameters, moving from a risky to a very attractive valuation grade. Despite a stagnant share price at ₹111.00, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value within the Pharmaceuticals & Biotechnology sector.

Sotac Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Jan 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

At Rs 111.3, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Sotac Pharmaceuticals Ltd locked at its upper circuit of 5.0% on 12 May 2026, with buyers queuing and no sellers willing to part with shares.

Sotac Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

At Rs 111.15, sellers were still queuing — but there were no buyers willing to take the other side. Sotac Pharmaceuticals Ltd locked at its lower circuit of 5.0% on 4 May 2026, with unfilled sell orders and a frozen price.

Sotac Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Jan 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 28 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Sotac Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jan 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 17 April 2026, providing investors with an up-to-date view of its performance and outlook.

At Rs 107.10, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Sotac Pharmaceuticals Ltd locked at its upper circuit of 5% on 8 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Sotac Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 06 April 2026, providing investors with the latest insights into the company’s performance and outlook.

At Rs 109.25, sellers were still queuing — but there were no buyers willing to take the other side. Sotac Pharmaceuticals Ltd locked at its lower circuit of 5.0% on 30 Mar 2026, with unfilled sell orders and a frozen price, reflecting a constrained exit environment for shareholders.

Sotac Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sotac Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Jan 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 15 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sotac Pharmaceuticals Ltd witnessed a robust surge in its share price on 10 Mar 2026, hitting the upper circuit limit of 5.0% to close at ₹116.55. This sharp rally was driven by intense buying interest, resulting in a maximum permissible daily gain and a regulatory freeze on further trading, underscoring the stock’s heightened demand despite its micro-cap status and recent downgrade to a Strong Sell rating.

Sotac Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 03 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Sotac Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 February 2026, providing investors with the latest insights into its performance and outlook.

Sotac Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 18 Feb 2026, hitting its lower circuit price limit of ₹118.75. The stock plunged by 5.0% in a single trading session, reflecting intense selling pressure and panic among investors amid subdued market sentiment and falling participation.

Sotac Pharmaceuticals Ltd witnessed a remarkable surge on 10 Feb 2026, hitting its upper circuit limit of ₹124.20, marking a maximum daily gain of 4.99%. This sharp price movement was driven by robust buying interest, resulting in a regulatory trading freeze and highlighting significant unfilled demand in the micro-cap pharmaceutical stock.

Sotac Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 January 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 09 February 2026, providing investors with the latest perspective on the company’s position.